Any systemic treatment vs placebo
Tildrakizumab · people with chronic plaque psoriasis
Any systemic treatment leads to higher tildrakizumab compared with placebo (high certainty).
2 findings from 1 review
- Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis 2020 · Cochrane Headline outcomes onlyRR 17.08 [12.93, 22.56]3 studies · 1903 participantsHigh
- Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis 2020 · Cochrane Headline outcomes onlyRR 0.84 [0.39, 1.83]3 studies · 1904 participantsModerate